Form 4: Adagio Medical Director Salmon Receives Stock Options

Adagio Medical Holdings, Inc. Director Sean Salmon was granted 90,000 non-qualified stock options with an exercise price of $0.8779, vesting over 36 months.

Summary

• Sean Salmon, a Director of Adagio Medical Holdings, Inc. (ADGM), was granted 90,000 non-qualified stock options.
• The options have an exercise price of $0.8779 per share.
• The grant date for these options was December 11, 2025.
• The options will vest in 36 equal monthly installments, commencing on January 11, 2026.
• Vesting is contingent upon Mr. Salmon's continued service to the company through each vesting date.
• The options have an expiration date of December 10, 2035.
• Following this transaction, Mr. Salmon beneficially owns 90,000 derivative securities directly.

Sentiment

Score: 6

Explanation: The filing reports a standard compensation event (stock option grant) to a director, which is generally viewed as a neutral to slightly positive development as it aligns management interests with shareholders. It does not contain any unexpected positive or negative financial news.

Positives

• The grant of 90,000 non-qualified stock options to Director Sean Salmon aligns his interests with those of shareholders, incentivizing long-term performance.
• The vesting schedule over 36 months encourages continued service and commitment from a key director.

Negatives

• No direct negatives are indicated in this Form 4 filing, which reports a standard compensation event.

Risks

• No specific risks are mentioned in this Form 4 filing. The primary risk associated with options is the potential for their value to decrease if the stock price falls below the exercise price.

Future Outlook

The vesting schedule for the granted stock options, commencing January 11, 2026, and continuing over 36 months, indicates an expectation of Sean Salmon's continued service as a Director for Adagio Medical Holdings, Inc.

Industry Context

The grant of stock options to a director is a common practice in the medical device and biotechnology industries, serving as a key component of executive and director compensation packages. This aligns the interests of leadership with long-term shareholder value creation.

Comparison to Industry Standards

• The grant of non-qualified stock options to a director is a standard compensation mechanism widely used across publicly traded companies, including those in the medical technology sector.
• The vesting schedule over 36 months is typical for incentivizing long-term commitment, comparable to practices at companies like Medtronic (MDT) or Boston Scientific (BSX) for their non-employee directors, though specific grant sizes and exercise prices vary based on company size, performance, and individual roles.
• The exercise price of $0.8779, likely the fair market value on the grant date, is standard for such grants, ensuring the options have intrinsic value only if the stock price appreciates.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for increased alignment of director's interests with shareholder value creation.

Next Steps

• The options will begin vesting in 36 equal monthly installments starting January 11, 2026.
• Sean Salmon's continued service to the company is required for the options to vest.

Key Dates

Keywords

Adagio Medical Holdings, ADGM, Sean Salmon, Stock Options, Non-qualified options, Director compensation, Insider transaction, Equity grant, Vesting schedule, SEC Form 4